JARDIANCE® provides triple protection in your patients with CRM conditions:
reduced risk of CV death
or kidney disease progression*1,2
or kidney disease progression*1,2
reduced risk of CV death
or hospitalisation for heart failure†3,4
or hospitalisation for heart failure†3,4
reduced risk of CV death‡5
Prof. Christoph Wanner - How relevant is the broad patient population within EMPA-KIDNEY for a general practitioner's daily practice?
14/03/2024 | Author: Boehringer Ingelheim
Document ID: PC-MY-103563
RELATED CONTENT
0:52
Prof. Christoph Wanner - What is a typical patient that may benefit from the EMPA-KIDNEY trial results?
1:14
Prof. Christoph Wanner - How do you interpret the importance of EMPA-KIDNEY results with regards to the treatment of patients with CKD?
0:50
Prof. Christoph Wanner - How do you interpret the results of the primary outcome of EMPA-KIDNEY?
1:06
Prof. Christoph Wanner - For you as a nephrologist in your daily practice, what is the most impactful outcome that was shown in the EMPA-KIDNEY¹ trial?
0:48
Prof. Christoph Wanner - How does this early intervention impact the heart?
0:49